Samsung Epis Holdings subsidiary Samsung Bioepis said on the 18th that it presented study results on the therapeutic efficacy and safety of the autoimmune disease treatment "Adalloce" at the Korean College of Rheumatology International Congress (KCR 2026).
Samsung Bioepis took part in KCR 2026, held at the Conrad Seoul in Yeouido from the 14th to the 16th, and unveiled two studies related to Adalloce, a biosimilar of AbbVie's autoimmune disease treatment Humira (adalimumab).
First, in an observational study of 488 patients with rheumatoid arthritis and ankylosing spondylitis, the health-related quality-of-life index (EQ-5D-5L) improved by an average of 0.09 points after 52 weeks of Adalloce administration. The patient-reported health status score (EQ-VAS) also rose by an average of 11.90 points.
Samsung Bioepis also announced post-marketing surveillance (PMS) results of 303 patients across all approved indications for Adalloce. The incidence of adverse events was 29.7%, and the incidence of serious adverse events was 2.6%, which the company said was similar to safety results observed in prior clinical trials.
The company added that even when patients who had been using existing adalimumab formulations switched to Adalloce, disease activity scores remained stable, confirming that continued disease management is possible after switching to a biosimilar.
In addition, during the congress, Samsung Bioepis held a symposium inviting domestic and overseas medical professionals to share the latest trends and guidelines in autoimmune disease treatment. At the corporations booth in the exhibition hall, the company also introduced its products and research achievements to medical professionals and industry officials.
Samsung Bioepis has currently received approval for 11 biosimilars in Korea. Of these, four autoimmune disease treatments and one rare disease treatment are sold directly, while treatments for ophthalmic, oncology, and bone diseases are supplied in collaboration with specialized distributors.
Kil Ji-hun, head of the medical team (executive director) at Samsung Bioepis, said, "Through presentations at an international congress, we confirmed the potential for our product to contribute to treatment and quality-of-life improvement for patients in Korea," and added, "We will continue efforts to expand patient access to high-quality medicines."